Introduction
Culprit artery reperfusion with fibrinolytic therapy and/or percutaneous coronary intervention (PCI) is the established treatment for ST-elevation myocardial infarction (STEMI), with rapid access to optimised treatment providing the best outcome.1,2 Although timely primary PCI compared with fibrinolytic therapy for STEMI has demonstrated potential benefits in mortality and morbidity1 and pilot primary PCI services are currently being evaluated around the UK, fibrinolytic therapy remains the most common form of reperfusion treatment. An area of ongoing research is the optimisation of adjuvant treatment, in particular the anticoagu